전이성 흑색종 암 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Metastatic Melanoma Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 6,876,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,043,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,695,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 전이성 흑색종 암 진단 시장의 상세 분석을 시행하고, 세계 상황을 심층 분석한 종합적 보고서를 정리했습니다. 이 상세 출판물은 시장 역학, 동향, 기회, 과제에 관한 귀중한 인사이트를 제공하고, 구조의 완전한 개요를 제공합니다. 독점 데이터와 통계의 지원으로 조사는 2024-2033년의 전이성 흑색종 암 진단 시장의 예측 성장 궤도를 예측합니다.

세계의 전이성 흑색종 암 진단 시장은 2024년에 37억 달러의 매출을 창출할 것으로 예측됩니다. CAGR 7.8%로 성장할 것으로 예측되며, 2033년말까지는 72억 달러의 평가액에 달할 것으로 예측됩니다.

주요 인사이트

• 전이성 흑색종 암 진단 시장 규모(2024년) : 37억 달러
• 예측 시장 금액(2033년) : 72억 달러
• 세계 시장 성장률(CAGR, 2024-2033년) : 7.8%

전이성 흑색종 암 진단 시장 - 리포트 범위 :

전이성 흑색종 암 진단은 심각한 피부암인 흑색종을 조기에 발견하고 치료하는 데 중요한 역할을 합니다. 진단 툴 및 진단 방법에는 영상 검사, 생검, 분자 검사, 혈액 검사 등이 포함되며, 흑색종이 신체의 다른 부위로 전이되었는지 확인하는 데 도움이 됩니다. 이 시장은 병원, 클리닉, 진단 실험실 및 연구 기관을 대상으로 다양한 진단 기술과 서비스를 제공합니다. 시장 성장의 원동력은 흑색종 발병률 증가, 진단 기술 발전, 조기 발견 및 맞춤형 의료에 대한 중요성 증가입니다.

시장 성장의 촉진요인:

세계 전이성 흑색종 암 진단 시장은 효율적인 조기 진단 솔루션이 필요한 흑색종 발병률 증가와 같은 몇 가지 중요한 요인에 의해 주도되고 있습니다. 차세대 염기서열 분석(NGS) 및 액체생검과 같은 진단 툴의 기술 발전은 흑색종 검출의 정확성과 속도를 향상시켜 시장 확대에 기여하고 있습니다. 맞춤형 의료와 표적 치료의 채택이 증가하면서 흑색종에 대한 상세한 유전자 및 분자 정보를 제공할 수 있는 고급 진단 방법에 대한 수요가 더욱 증가하고 있습니다. 또한 피부암에 대한 의식의 향상와 검진 프로그램이 조기 진단을 촉진하여 치료 성과 향상과 시장 성장의 원동력이 되고 있습니다.

시장 성장 억제요인 :

전이성 흑색종 진단 시장은 유망한 성장세를 보이고 있지만, 일부 지역에서는 높은 비용과 고급 진단 툴의 제한적인 접근성 등의 문제에 직면해 있습니다. 특히 의료 예산이 제한된 신흥 국가에서는 진단 절차 및 장비의 고비용이 보급에 걸림돌이 될 수 있습니다. 또한 새로운 진단 기술에 대한 규제 장벽과 까다로운 승인 절차도 시장 진입과 상용화를 지연시키는 요인으로 작용하고 있습니다. 또한 지역마다 진단 검사에 대한 보상 정책이 상이한 것도 시장 성장에 영향을 미치며, 제조업체와 의료 서비스 프로바이더는 복잡한 규제 환경을 헤쳐나가야 합니다.

시장 기회 :

전이성 흑색종 암 진단 시장은 진단 기술 혁신, 의료 인프라 확대, 암 연구에 대한 투자 증가로 인해 큰 성장 기회를 맞이하고 있습니다. 진단 툴에 인공지능(AI)과 머신러닝(ML)을 통합하면 정확도와 효율성을 향상시켜 조기 발견과 개인화된 치료 계획에 새로운 가능성을 제시할 수 있습니다. 액체생검과 같은 비침습적, 저침습적 진단 방법의 개척은 환자에게 더 안전하고 편리한 선택권을 제공하고 시장 범위를 확대할 것입니다. 전략적 파트너십, 연구 협력 및 신흥 시장에 대한 투자는 이러한 기회를 활용하고 시장 리더십을 유지하는 데 필수적입니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위 / 분류
• 시장의 정의 / 범위 / 제한
• 포함 사항·제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 혁신 / 개발 동향

제4장 주요 성공요인

• 질병 역학 : 지역별
• 규제 상황
• 검사 채택률
• 기술의 진보
• 환불 시나리오
• PESTEL 분석
• Porter의 산업 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 검사별
  • 서비스 프로바이더별
  • 국가별
• 2024년 시장 시나리오

제7장 세계의 전이성 흑색종 암 진단 시장 수요 분석

• 과거 시장 금액 분석, 2019-2023년
• 현재 및 향후 시장 금액 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대액의 기회 분석

제8장 세계의 전이성 흑색종 암 진단 시장 분석 : 검사별

• 서론 / 주요 조사 결과
• 과거 시장 규모 분석 : 검사별, 2019-2023년
• 현재 및 향후 시장 규모의 분석과 예측 : 검사별, 2024-2033년
  • 생검
  • 흉부 X선
  • 초음파
  • CT 스캔
  • MRI
  • PET 스캔
• 시장의 매력 분석 : 검사별

제9장 세계의 전이성 흑색종 암 진단 시장 분석 : 서비스 프로바이더별

• 서론 / 주요 조사 결과
• 과거 시장 규모 분석 : 서비스 프로바이더별, 2019-2023년
• 현재 및 향후 시장 규모 분석과 예측 : 서비스 프로바이더별, 2024-2033년
  • 병원
  • 병리학 연구실
  • 암연구 센터
• 시장의 매력 분석 : 서비스 프로바이더별

제10장 세계의 전이성 흑색종 암 진단 시장 분석 : 지역별

• 서론
• 과거 시장 규모 분석 : 지역별, 2019-2023년
• 현재 및 향후 시장 금액의 분석과 예측 : 지역별, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제11장 북미의 전이성 흑색종 암 진단 시장 분석

제12장 라틴아메리카의 전이성 흑색종 암 진단 시장 분석

제13장 유럽의 전이성 흑색종 암 진단 시장 분석

제14장 동아시아의 전이성 흑색종 암 진단 시장 분석

제15장 남아시아의 전이성 흑색종 암 진단 시장 분석

제16장 오세아니아의 전이성 흑색종 암 진단 시장

제17장 중동 및 아프리카(MEA) 전이성 흑색종 암 진단 시장 분석

제18장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁의 상세
  • Amgen Inc
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Novartis AG
  • F-Hoffmann-La Roche Ltd
  • Biomerieux
  • Quest diagnostics
  • Agilent Technologies Inc
  • Myriad Genetics Inc
  • Qiagen

제19장 사용되는 전제 조건과 두자어

제20장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research recently conducted an in-depth analysis of the Metastatic Melanoma Cancer Diagnostics Market, resulting in a comprehensive report that delves extensively into its global landscape. This detailed publication provides valuable insights into the market's dynamics, trends, opportunities, and challenges, offering a thorough overview of its structure. With the support of exclusive data and statistics, the research predicts the anticipated growth trajectory of the Metastatic Melanoma Cancer Diagnostics Market spanning from 2024 to 2033.

The global metastatic melanoma cancer diagnostics market is expected to generate revenue of USD 3.7 billion in 2024. Projected to grow at a compound annual growth rate (CAGR) of 7.8%, the market is anticipated to reach a valuation of USD 7.2 billion by the end of 2033.

Key Insights:

• Metastatic Melanoma Cancer Diagnostics Market Size (2024): USD 3.7 billion
• Projected Market Value (2033):USD 7.2 billion
• Global Market Growth Rate (CAGR 2024-2033):7.8%

Metastatic Melanoma Cancer Diagnostics Market - Report Scope:

Metastatic melanoma cancer diagnostics play a crucial role in the early detection and treatment of melanoma, a serious form of skin cancer. Diagnostics tools and methods include imaging tests, biopsies, molecular tests, and blood tests that help in identifying the spread of melanoma to other parts of the body. The market caters to hospitals, clinics, diagnostic laboratories, and research institutes, offering a range of diagnostic technologies and services. Market growth is driven by increasing incidence rates of melanoma, advancements in diagnostic technologies, and a growing emphasis on early detection and personalized medicine.

Market Growth Drivers:

The global metastatic melanoma cancer diagnostics market is propelled by several key factors, including rising melanoma incidence rates, which necessitate efficient and early diagnostic solutions. Technological advancements in diagnostic tools, such as next-generation sequencing (NGS) and liquid biopsy, enhance the accuracy and speed of melanoma detection, contributing to market expansion. The increasing adoption of personalized medicine and targeted therapies further drives demand for advanced diagnostic methods that can provide detailed genetic and molecular information about melanoma. Additionally, heightened awareness and screening programs for skin cancer encourage early diagnosis, improving treatment outcomes and fueling market growth.

Market Restraints:

Despite promising growth prospects, the metastatic melanoma cancer diagnostics market faces challenges related to high costs and limited accessibility of advanced diagnostic tools in some regions. The high cost of diagnostic procedures and equipment can be a barrier to widespread adoption, particularly in emerging economies with constrained healthcare budgets. Regulatory hurdles and stringent approval processes for new diagnostic technologies can also delay market entry and commercialization. Furthermore, variability in reimbursement policies for diagnostic tests across different regions impacts market growth, requiring manufacturers and healthcare providers to navigate complex regulatory landscapes.

Market Opportunities:

The metastatic melanoma cancer diagnostics market presents significant growth opportunities driven by innovations in diagnostic technologies, expanding healthcare infrastructure, and increasing investment in cancer research. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools enhances accuracy and efficiency, offering new possibilities for early detection and personalized treatment plans. The development of non-invasive and minimally invasive diagnostic methods, such as liquid biopsy, provides safer and more convenient options for patients, broadening the market scope. Strategic partnerships, research collaborations, and investment in emerging markets are essential to capitalize on these opportunities and sustain market leadership.

Competitive Intelligence and Business Strategy:

Leading players in the global metastatic melanoma cancer diagnostics market, including F. Hoffmann-La Roche Ltd., Illumina, Inc., and Agilent Technologies, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic solutions, including NGS, liquid biopsy, and molecular diagnostics, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, research institutes, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving melanoma diagnostics landscape.

Key Companies Profiled:

• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Castle Biosciences, Inc.

Key Segments Covered in Metastatic Melanoma Cancer Diagnostics Industry Research

Test:

• Biopsy
• Chest X-ray
• Ultrasound
• CT Scan
• MRI
• PET SCAN

Service Provider:

• Hospitals
• Pathology Laboratories
• Cancer Research Centres

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Disease Epidemiology, by Region
• 4.2. Regulatory Landscape
• 4.3. Test Adoption Rates
• 4.4. Technological Advancements
• 4.5. Reimbursement Scenario
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Cancer Diagnostics Market Overview
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Test Adoption Rates
  • 5.2.2. Frequency of New Test Launches
  • 5.2.3. Regulatory Scenario
  • 5.2.4. Increasing Number of Cancer Prevention Techniques
  • 5.2.5. Epidemiology of Skin Cancer
  • 5.2.6. Reimbursement Scenario
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Test
  • 6.1.2. By Service Provider
  • 6.1.3. By Country
• 6.2. 2024 Market Scenario

7. Global Metastatic Melanoma Cancer Diagnostics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Test

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Test, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Test, 2024-2033
  • 8.3.1. Biopsy
    • 8.3.1.1. Local excision/excisional biopsy
    • 8.3.1.2. Punch biopsy
    • 8.3.1.3. Shave biopsy
    • 8.3.1.4. Fine needle aspiration (FNA) biopsy
    • 8.3.1.5. Sentinel lymph node biopsy
  • 8.3.2. Chest X-ray
  • 8.3.3. Ultrasound
  • 8.3.4. CT Scan
  • 8.3.5. MRI
  • 8.3.6. PET SCAN
• 8.4. Market Attractiveness Analysis By Test

9. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Service Provider

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Service Provider, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Service Provider, 2024-2033
  • 9.3.1. Hospitals
  • 9.3.2. Pathology Laboratories
  • 9.3.3. Cancer Research Centers
• 9.4. Market Attractiveness Analysis By Service Provider

10. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Region, 2024-2033
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Test
  • 11.3.3. By Service Provider
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Test
  • 11.4.3. By Service Provider
• 11.5. Market Trends
• 11.6. Drivers and Restraints - Impact Analysis
• 11.7. Country Level Analysis & Forecast
  • 11.7.1. U.S. Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 11.7.1.1. Introduction
    • 11.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.7.1.2.1. By Test
      • 11.7.1.2.2. By Service Provider
  • 11.7.2. Canada Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 11.7.2.1. Introduction
    • 11.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.7.2.2.1. By Test
      • 11.7.2.2.2. By Service Provider

12. Latin America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. Mexico
    • 12.3.1.2. Brazil
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Test
  • 12.3.3. By Service Provider
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Test
  • 12.4.3. By Service Provider
• 12.5. Market Trends
• 12.6. Drivers and Restraints - Impact Analysis
• 12.7. Country Level Analysis & Forecast
  • 12.7.1. Mexico Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.1.1. Introduction
    • 12.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.1.2.1. By Test
      • 12.7.1.2.2. By Service Provider
  • 12.7.2. Brazil Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.2.1. Introduction
    • 12.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.2.2.1. By Test
      • 12.7.2.2.2. By Service Provider
  • 12.7.3. Argentina Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 12.7.3.1. Introduction
    • 12.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.7.3.2.1. By Test
      • 12.7.3.2.2. By Service Provider

13. Europe Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Test
  • 13.3.3. By Service Provider
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Test
  • 13.4.3. By Service Provider
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Country Level Analysis & Forecast
  • 13.7.1. Germany Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.1.1. Introduction
    • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.1.2.1. By Test
      • 13.7.1.2.2. By Service Provider
  • 13.7.2. Italy Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.2.1. Introduction
    • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.2.2.1. By Test
      • 13.7.2.2.2. By Service Provider
  • 13.7.3. France Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.3.1. Introduction
    • 13.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.3.2.1. By Test
      • 13.7.3.2.2. By Service Provider
  • 13.7.4. U.K. Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.4.1. Introduction
    • 13.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.4.2.1. By Test
      • 13.7.4.2.2. By Service Provider
  • 13.7.5. Spain Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.5.1. Introduction
    • 13.7.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.5.2.1. By Test
      • 13.7.5.2.2. By Service Provider
  • 13.7.6. BENELUX Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.6.1. Introduction
    • 13.7.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.6.2.1. By Test
      • 13.7.6.2.2. By Service Provider
  • 13.7.7. Russia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 13.7.7.1. Introduction
    • 13.7.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.7.2.1. By Test
      • 13.7.7.2.2. By Service Provider

14. East Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
  • 14.3.2. By Test
  • 14.3.3. By Service Provider
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Test
  • 14.4.3. By Service Provider
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Country Level Analysis & Forecast
  • 14.7.1. China Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.1.1. Introduction
    • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.1.2.1. By Test
      • 14.7.1.2.2. By Service Provider
  • 14.7.2. Japan Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.2.1. Introduction
    • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.2.2.1. By Test
      • 14.7.2.2.2. By Service Provider
  • 14.7.3. South Korea Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 14.7.3.1. Introduction
    • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.3.2.1. By Test
      • 14.7.3.2.2. By Service Provider

15. South Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Indonesia
    • 15.3.1.3. Malaysia
    • 15.3.1.4. Thailand
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Test
  • 15.3.3. By Service Provider
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Test
  • 15.4.3. By Service Provider
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Country Level Analysis & Forecast
  • 15.7.1. India Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.1.1. Introduction
    • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.1.2.1. By Test
      • 15.7.1.2.2. By Service Provider
  • 15.7.2. Indonesia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.2.1. Introduction
    • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.2.2.1. By Test
      • 15.7.2.2.2. By Service Provider
  • 15.7.3. Malaysia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.3.1. Introduction
    • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.3.2.1. By Test
      • 15.7.3.2.2. By Service Provider
  • 15.7.4. Thailand Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 15.7.4.1. Introduction
    • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.4.2.1. By Test
      • 15.7.4.2.2. By Service Provider

16. Oceania Metastatic Melanoma Cancer Diagnostics Market 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Test
  • 16.3.3. By Service Provider
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Test
  • 16.4.3. By Service Provider
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Country Level Analysis & Forecast
  • 16.7.1. Australia Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 16.7.1.1. Introduction
    • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.1.2.1. By Test
      • 16.7.1.2.2. By Service Provider
  • 16.7.2. New Zealand Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 16.7.2.1. Introduction
    • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.2.2.1. By Test
      • 16.7.2.2.2. By Service Provider

17. Middle East and Africa (MEA) Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkey
    • 17.3.1.3. North Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Test
  • 17.3.3. By Service Provider
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Test
  • 17.4.3. By Service Provider
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. GCC Countries Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.1.2.1. By Test
      • 17.7.1.2.2. By Service Provider
  • 17.7.2. Turkey Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.2.2.1. By Test
      • 17.7.2.2.2. By Service Provider
  • 17.7.3. South Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.3.1. Introduction
    • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.3.2.1. By Test
      • 17.7.3.2.2. By Service Provider
  • 17.7.4. North Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
    • 17.7.4.1. Introduction
    • 17.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.4.2.1. By Test
      • 17.7.4.2.2. By Service Provider

18. Competition Analysis

• 18.1. Competition Dashboard
• 18.2. Competition Benchmarking
• 18.3. Competition Deep Dive
  • 18.3.1. Amgen Inc
    • 18.3.1.1. Overview
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. Sales Footprint
    • 18.3.1.4. Strategy Overview
  • 18.3.2. Abbott Laboratories
    • 18.3.2.1. Overview
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. Sales Footprint
    • 18.3.2.4. Strategy Overview
  • 18.3.3. Bristol-Myers Squibb
    • 18.3.3.1. Overview
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. Sales Footprint
    • 18.3.3.4. Strategy Overview
  • 18.3.4. Novartis AG
    • 18.3.4.1. Overview
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. Sales Footprint
    • 18.3.4.4. Strategy Overview
  • 18.3.5. F-Hoffmann-La Roche Ltd
    • 18.3.5.1. Overview
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. Sales Footprint
    • 18.3.5.4. Strategy Overview
  • 18.3.6. Biomerieux
    • 18.3.6.1. Overview
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. Sales Footprint
    • 18.3.6.4. Strategy Overview
  • 18.3.7. Quest diagnostics
    • 18.3.7.1. Overview
    • 18.3.7.2. Product Portfolio
    • 18.3.7.3. Sales Footprint
    • 18.3.7.4. Strategy Overview
  • 18.3.8. Agilent Technologies Inc
    • 18.3.8.1. Overview
    • 18.3.8.2. Product Portfolio
    • 18.3.8.3. Sales Footprint
    • 18.3.8.4. Strategy Overview
  • 18.3.9. Myriad Genetics Inc
    • 18.3.9.1. Overview
    • 18.3.9.2. Product Portfolio
    • 18.3.9.3. Sales Footprint
    • 18.3.9.4. Strategy Overview
  • 18.3.10. Qiagen
    • 18.3.10.1. Overview
    • 18.3.10.2. Product Portfolio
    • 18.3.10.3. Sales Footprint
    • 18.3.10.4. Strategy Overview

19. Assumptions and Acronyms Used

20. Research Methodology

관련자료